Floatz logo

144 assets in Colorectal Carcinoma

Therapeutic assets addressing Colorectal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Dabrafenib
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Defactinib
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Fexagratinib
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Gsk-2636771
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Ipatasertib
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Larotrectinib
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
muc1 peptide-poly-iclc vaccine
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Muc-1 Peptide Vaccine
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Neoantigen Dendritic Cell Vaccine
Colorectal Carcinoma
National Cancer Centre, SingaporeP2CCC (51)
Nogapendekin Alfa
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Obeticholic Acid
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Osimertinib
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Pertuzumab
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Relatlimab
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Sapanisertib
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Sotorasib
Colorectal Carcinoma
Federation Francophone de Cancerologie DigestiveP2CCC (51)
Tpst-1495
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Trastuzumab
Colorectal Carcinoma
Seagen, a wholly owned subsidiary of PfizerP2CCC (51)
Trastuzumab Emtansine
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Tucatinib
Colorectal Carcinoma
Seagen, a wholly owned subsidiary of PfizerP2CCC (51)
Ulixertinib
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Vismodegib
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Zanidatamab
Colorectal Carcinoma
Emory UniversityP2CCC (51)
Adavosertib
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (50)
Rintatolimod
Colorectal Carcinoma
Roswell Park Cancer InstituteP2CCC (50)
Taselisib
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (50)
Vemurafenib
Colorectal Carcinoma
Shanghai Changzheng HospitalP2CCC (50)
Copanlisib
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (49)
Immunoglobulin G1, Anti-(Human Interleukin-1 Receptor Accessory Protein) (Human-Mus Musculus Monoclonal Can04 .Gamma.1-Chain), Disulfide With Human-Mus Musculus Monoclonal Can04 .Kappa.-Chain, Dimer
Colorectal Carcinoma
Dan FengP1/2CCC (48)
Methadone
Colorectal Carcinoma
AIO-Studien-gGmbHP1/2CCC (48)
Opnurasib
Colorectal Carcinoma
Novartis PharmaceuticalsP1/2CCC (48)
Pirfenidone
Colorectal Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyP1/2CCC (48)
Tuvusertib
Colorectal Carcinoma
National Cancer Institute (NCI)P1/2CCC (48)
5-ala
Colorectal Carcinoma
Roswell Park Cancer InstituteP1/2CC (47)
Devimistat
Colorectal Carcinoma
Northwestern UniversityP2CC (47)
SX682
Colorectal Carcinoma
M.D. Anderson Cancer CenterP1/2CC (47)
Temuterkib
Colorectal Carcinoma
M.D. Anderson Cancer CenterP1/2CC (47)
Polypepi1018
Colorectal Carcinoma
Mayo ClinicP1CC (46)
Avutometinib
Colorectal Carcinoma
University of ChicagoP1/2CC (45)
Bxq-350
Colorectal Carcinoma
Bexion Pharmaceuticals, Inc.P1/2CC (45)
tno155
Colorectal Carcinoma
Novartis PharmaceuticalsP1/2CC (45)
Toripalimab
Colorectal Carcinoma
Dan FengP1/2CC (45)
[111in]-fpi-2107
Colorectal Carcinoma
AstraZenecaP1CC (43)
1H-Isoindol-1-one, 2,3-dihydro-2-[3-[cis-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methyl-1-piperidinyl]methyl]-4-(trifluoromethyl)-
Colorectal Carcinoma
Nurix Therapeutics, Inc.P1CC (43)
[225ac]-fpi-2068
Colorectal Carcinoma
AstraZenecaP1CC (43)
Berzosertib
Colorectal Carcinoma
National Cancer Institute (NCI)P1CC (43)
Bet Bromodomain Inhibitor Zen-3694
Colorectal Carcinoma
National Cancer Institute (NCI)P1CC (43)
cp-383
Colorectal Carcinoma
Tasca TherapeuticsP1/2CC (43)
Dynamos
Colorectal Carcinoma
Fudan UniversityP1/2CC (43)
Showing 51 to 100 of 144 assets
PreviousPage 2 of 3Next